Free and open to the public, this community-centric event is modeled after the UW-Madison School of Medicine and Public Health’s “Mini-Med School” programs. Our Spring 2019 Saving Sight Session will feature the leading research from the Department of Ophthalmology and Visual Sciences at the University of Wisconsin. Please join us for this exciting discussion and light dinner.
register here by april 1, 2019
“An Update on Diabetic Retinopathy: Diagnosis and Treatments“
ABOUT DR. GOTTLIEB
Justin L. Gottlieb, MD, is an ophthalmologist who sees patients in Madison, WI, and Rockford, IL, and has served as principal investigator for numerous clinical trials in diabetic retinopathy, macular degeneration and other retinal diseases. Dr. Gottlieb is principal investigator for the Madison site of the Diabetic Retinopathy Clinical Research Network (DRCR), and served as co-principal investigator for the landmark Age-Related Eye Disease Study (AREDS), which investigated the effect of antioxidant vitamins and zinc on macular degeneration and cataract.
- 5:30-6:00PM – Registration and light dinner served (buffet style)
- 6:00-7:00PM – Introduction >> Presentation >> Question/Answer Discussion
ABOUT SAVING SIGHT SESSIONS
Free and open to the public, this community-centric event is modeled after the UW-Madison School of Medicine and Public Health’s “Mini-Med School” programs. Our Spring 2019 Saving Sight Session will feature the leading research from Justin L. Gottlieb, MD, Professor in the Department of Ophthalmology and Visual Sciences at the University of Wisconsin. Please join us for this exciting discussion and light dinner.
register here by april 1, 2019
We welcome David Antonetti, PhD, Professor of Ophthalmology and Visual Sciences, Professor of Molecular and Integrative Physiology from Kellogg Eye Center at the University of Michigan, as he presents:
“Blood-Retinal Barrier Regulation in Diabetic Retinopathy: New Insight and Opportunities.”
We hope you will join us for this exciting discussion. Please RSVP for the event by emailing Jenny Priebe: email@example.com
About Dr. Antonetti’s Research:
Our long-term goal is to contribute to the development of novel treatments to prevent or reverse the debilitating loss of vision from diabetes. Our current research focuses on understanding how the blood-retinal barrier normally develops in the retina and how to restore normal barrier properties in diseases like diabetic retinopathy. This research has led our team to develop methods to regenerate normal retinal vascular function in models of diabetes. Ultimately, these studies may provide a path for the development of therapies to restore the blood-neural barrier in a variety of diseases including diabetic retinopathy or brain tumors.
ABOUT DR. ANTONETTI:
Dr. Antonetti received his PhD in Cellular and Molecular Biology at The Penn State College of Medicine under the direction of Dr. Leonard Jim Jefferson and was a post-doctoral fellow in Cellular and Molecular Physiology at the Joslin Diabetes Center at Harvard Medical School under the direction of Dr. C. Ronald Kahn. Upon returning to Penn State, he was one of the first to bring high-level signal transduction expertise to the problem of diabetic retinopathy and the blood-retinal barrier. Over the last 20 years, he has become one of the world’s leading experts in mechanisms of vascular permeability in diabetic retinopathy, the role of the blood retinal barrier in normal physiology, and the molecular mechanisms that underlie angiogenesis and neovascularization. These efforts have allowed him to develop new experimental treatments that show promising pre-clinical results. He has received awards including the Jules Francois Prize for Young Investigator at Ophthalmologia Beligica, the Hinkle Society Mid-career Translational Research Award, and the Most Inspirational Teacher Award for graduate education at Penn State. He also holds the very prestigious Jules and Doris Stein Professorship from Research to Prevent Blindness. His work has been noted by presentations at key meetings such as the American Diabetes Association, the International Symposium of the Blood-Brain Barrier, Gordon Research Conferences, and the International Symposium on Signal Transduction at the Blood-Brain and Blood-Retina Barriers. Of particular note, his translational impact has been recognized by clinicians by his presentations at the American Uveitis Society, the American Academy of Ophthalmology, the ARVO Vision Innovation and Venture forum, and the University of Pittsburgh, Washington University, and Trinity College in Dublin.
Please join us for a collective exploration into the ever-changing landscape of sight saving discovery with colleagues and peers from across the globe.
Our next discussion will feature James Tahara Handa, MD, Robert Bond Welch, MD, Professor, Professor of Ophthalmology at Wilmer Eye Institute of Johns Hopkins University.
About Dr. Handa
Dr. Handa is the Robert Bond Welch, MD, Professor of Ophthalmology at the Wilmer Eye Institute. He specializes in medical and surgical management of complex vitreoretinal diseases such as age-related macular degeneration, diabetic retinopathy, retinal detachment, retinopathy of prematurity and other pediatric retinal diseases. He also has expertise in intraocular oncology and manages patients with choroidal melanomas and metastatic tumors of the eye. Not only is he a highly skilled surgeon and clinician, but he also devotes significant effort to research related to the early causes of age-related macular degeneration using molecular pathological approaches to understand how the eye transforms from normal aging to early disease. Dr. Handa is currently the Wilmer Eye Institute’s implanting surgeon for the Argus II retinal chip implant, which was recently approved by the FDA after Dr. Handa participated in the clinical trial leading to its approval.